Abstract: The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is needed directly into a large tissue culture flask, and passaged so more than three times.

Abstract: Compositions for delaying, attenuating or preventing cardiac remodeling following cardiac injury contain fibroblast cells in a dosage providing an effective amount to delay, attenuate or prevent cardiac remodeling following cardiac injury. These cells are obtained by biopsy, preferably from the patient, then cultured and proliferated prior to use. It has been discovered that certain subpopulations of these cells are even better suited for repair or regeneration of tissue, the cells exhibiting properties similar to stem cells or multipotent cells. In a preferred embodiment, the cells are administered to delay, attenuate or prevent cardiac remodeling following cardiac injury.

Abstract: Personalized skin-specific topical formulations containing conditioned medium obtained from cultures of fibroblasts has been developed. Unlike other topical formulations, these formulations are specific for the recipient-skin type specific, and conditioned medium is obtained from a subject with desired skin characteristics. For example, since African American skin is known to wrinkle less and later than Caucasian skin, conditioned medium may be obtained from African American skin for application to pale skin. In another embodiment, the fibroblasts are obtained from young skin for administration to older skin. In still another embodiment, the fibroblasts are obtained from skin that does not suffer from acne or discoloration, for application to skin that is prone to acne or discoloration. Examples of skin donor selection criteria include delayed wrinkling, small pores, resistance to sunburn, resistance to acne, uniform coloration or lack of blotching or age spots and good moisture retention.

Abstract: Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL administered three times approximately three to six weeks apart, of cells at a concentration of from 1.0-2.0×107 cells/mL.